📰 Michael Erman News
Page 36 - Michael Erman News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Michael Erman. Real-time updates on events, politics, business and more.
April 27, 2023
Drugmaker Merck & Co on Thursday posted better-than-expected first-quarter results on the strength of its blockbuster cancer immunotherapy Keytruda and human papillomavirus vaccine Gardasil.... | April 27, 2023
April 20, 2023
WASHINGTON (Reuters) - Use of the drug misoprostol on its own to terminate pregnancies is on the rise in the United States as providers seek a preemptive alternative while a ban on abortion pill mifepristone is being considered in court. | 06:02am
April 20, 2023
Use of the drug misoprostol on its own to terminate pregnancies is on the rise in the United States as providers seek a preemptive alternative while a ban on abortion pill mifepristone is being considered in court.
April 18, 2023
(Reuters) -The U.S. Food and Drug Administration on Tuesday authorized a second dose of Omicron-targeting COVID-19 vaccines for older adults as well as those with a weak immune system. | 12:12pm
April 17, 2023
By Michael Erman (Reuters) -Merck & Co said on Sunday it will buy Prometheus Biosciences Inc for about $10.8 billion, picking up a promising experimental treatment for ulcerative colitis and Crohn's disease and building up
April 16, 2023
By Julie Steenhuysen and Michael Erman (Reuters) - An experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immuno...
April 16, 2023
An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Mercks immunotherapy Keytruda... | April 16, 2023
April 16, 2023
An experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immunotherapy Keytruda cut the risk of death or recurrence of the most deadly skin cancer by 44% compared Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.
April 16, 2023
Merck & Co said on Sunday it will buy Prometheus Biosciences Inc for about $10.8 billion, picking up a promising experimental treatment for ulcerative colitis and Crohns disease and building up... | April 16, 2023
April 16, 2023
By Julie Steenhuysen and Michael Erman (Reuters) - An experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immuno...